Managers / Q1 2026
EQT Fund Management S.a r.l.
CIK 0001834239 · 51A BOULEVARD ROYAL, LUXEMBOURG, N4, L-2449 · 352 26 73 26 65
Summary
Eqt Fund Management S.A R.l. reported $1.0B in U.S.-listed holdings across 5 positions for Q1 2026.
The portfolio is heavily concentrated: WAY alone accounts for 58.8% of reported value.
Compared with Q4 2025, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 69.9% · $713M
- Other · 24.8% · $254M
- ADR · 5.3% · $54M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AGMBAGOMAB THERAPEUTICS NV | NEW | +5.14M | 5.14M | +$54M | $54M |
| WAYWAYSTAR HLDG CORP | HELD | +0 | 24.88M | −$215M | $600M |
| OCULIS HOLDING AG | HELD | +0 | 5.90M | +$39M | $157M |
| EVMNEVOMMUNE INC | HELD | +0 | 4.93M | +$29M | $113M |
| PHARVARIS N V | HELD | +0 | 3.42M | +$2M | $97M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | WAYWAYSTAR HLDG CORPhistory → | COM | 58.77% | $600M | 24.88M |
| 2 | OCULIS HOLDING AG | ORDINARY SHARES | 15.37% | $157M | 5.90M |
| 3 | EVMNEVOMMUNE INChistory → | COM SHS | 11.10% | $113M | 4.93M |
| 4 | PHARVARIS N V | COM | 9.48% | $97M | 3.42M |
| 5 | AGMBAGOMAB THERAPEUTICS NVhistory → | SPONSORED ADS | 5.28% | $54M | 5.14M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $1.0B | 5 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $1.1B | 4 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $1.9B | 4 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $0 | 1 | Oct 30, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $0 | 1 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $0 | 1 | Apr 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $0 | 1 | Feb 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $399M | 2 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $775M | 2 | Jul 21, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.